Dayang Chem (Hangzhou) Co., Ltd.
China
Product Name: (R)-α-Phenylcyclohexaneglycolic Acid 4-(Diethylamino)-2-butynyl Ester, Hydrochloride
Price: $Inquiry/100g $Inquiry/1kg $Inquiry/100kg $Inquiry/1000kg
Purity: 98.0%
Stocking Period: Inquiry
Contact: Ms Wang

1207344-05-5

1207344-05-5 structure

Name: (R)-α-Phenylcyclohexaneglycolic Acid 4-(Diethylamino)-2-butynyl Ester, Hydrochloride
Chemical Name: 0NX3818GCW
CAS Number: 1207344-05-5
Molecular Formula: C₂₂H₃₂ClNO₃
Molecular Weight: 393.95
Catalog: Signaling Pathways GPCR/G Protein mAChR
Create Date: 2018-06-18 03:01:54
Modify Date: 2024-02-22 20:07:06
(R)-Oxybutynin hydrochloride, a (R)-isomer of Oxybutynin hydrochloride, is an orally active muscarinic receptor antagonist. (R)-Oxybutynin hydrochloride has antimuscarinic, antispasmodic and anticholinergic activity, competitively antagonizes Carbachol-induced contractions. (R)-Oxybutynin hydrochloride can be used for researching incontinence due to neurogenic bladder dysfunction[1][2][3].

Name	0NX3818GCW
Synonyms	S547MDN7WX 24II7HX270 Ethanamine, N,N-diethyl-, hydrochloride (1:1) EINECS 216-139-7 JWB87T68BN N,N-Diethylethanamine hydrochloride (1:1) 0NX3818GCW L9F3D9RENQ Triethylammonium chloride Triethylamine hydrochloride MFCD00012500

Description	(R)-Oxybutynin hydrochloride, a (R)-isomer of Oxybutynin hydrochloride, is an orally active muscarinic receptor antagonist. (R)-Oxybutynin hydrochloride has antimuscarinic, antispasmodic and anticholinergic activity, competitively antagonizes Carbachol-induced contractions. (R)-Oxybutynin hydrochloride can be used for researching incontinence due to neurogenic bladder dysfunction[1][2][3].
Related Catalog	Signaling Pathways >> Neuronal Signaling >> mAChR Signaling Pathways >> GPCR/G Protein >> mAChR Research Areas >> Neurological Disease
References	[1]. Smith ER, et al. Comparison of the antimuscarinic and antispasmodic actions of racemic oxybutynin and desethyloxybutynin and their enantiomers with those of racemic terodiline. Arzneimittelforschung. 1998 Oct;48(10):1012-8. [2]. Siddiqui MA, et al. Oxybutynin extended-release: a review of its use in the management of overactive bladder. Drugs. 2004;64(8):885-912. [3]. Zobrist RH, et al. Pharmacokinetics of the R- and S-enantiomers of oxybutynin and N-desethyloxybutynin following oral and transdermal administration of the racemate in healthy volunteers. Pharm Res. 2001 Jul;18(7):1029-34.